Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

The effect of transfusion on immune responses in thalassemia.

Politou M, Komninaka V, Valsami S, Kapsimali V, Pouliakis A, Koutsouri T, Panayiotakopoulos G, Kotsianidis I, Voskaridou E.

Blood Cells Mol Dis. 2020 Mar 31;83:102425. doi: 10.1016/j.bcmd.2020.102425. [Epub ahead of print]

PMID:
32244102
2.

Immune Responses Raised in an Experimental Colon Carcinoma Model Following Oral Administration of Lactobacillus casei.

Aindelis G, Tiptiri-Kourpeti A, Lampri E, Spyridopoulou K, Lamprianidou E, Kotsianidis I, Ypsilantis P, Pappa A, Chlichlia K.

Cancers (Basel). 2020 Feb 5;12(2). pii: E368. doi: 10.3390/cancers12020368.

3.

Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry.

Diamantopoulos PT, Pappa V, Symeonidis A, Kotsianidis I, Galanopoulos A, Papadaki H, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Kotsopoulou M, Repousis P, Dimou M, Solomou E, Pontikoglou C, Kyriakakis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Panayiotidis P, Viniou NA.

Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):114-121. doi: 10.1016/j.clml.2019.09.614. Epub 2019 Sep 28.

PMID:
31884152
4.

Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.

Kazachenka A, Young GR, Attig J, Kordella C, Lamprianidou E, Zoulia E, Vrachiolias G, Papoutselis M, Bernard E, Papaemmanuil E, Kotsianidis I, Kassiotis G.

Genome Med. 2019 Dec 23;11(1):86. doi: 10.1186/s13073-019-0707-x.

5.

Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist.

Ng KW, Attig J, Young GR, Ottina E, Papamichos SI, Kotsianidis I, Kassiotis G.

Elife. 2019 Nov 15;8. pii: e50256. doi: 10.7554/eLife.50256.

6.

B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax.

Christoforidou A, Bezirgiannidou Z, Vrachiolias G, Papoutselis M, Spanoudakis E, Kotsianidis Ι.

Leuk Lymphoma. 2020 Mar;61(3):749-752. doi: 10.1080/10428194.2019.1689392. Epub 2019 Nov 12. No abstract available.

PMID:
31713446
7.

The STAT signaling profile at the single cell level reveals novel insights in the association of FOXP3+ T regulatory cells with recurrent spontaneous abortions before and after lymphocyte immunotherapy.

Lamprianidou E, Daniilidis M, Kordella C, Zoulia E, Nakou E, Gerofotis A, Vasilaki A, Pantos G, Kotsianidis I.

Clin Immunol. 2020 Jan;210:108261. doi: 10.1016/j.clim.2019.108261. Epub 2019 Nov 2.

PMID:
31689518
8.

Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma.

Petrakis I, Kontogiorgis C, Nena E, Athanasakis K, Gougoula V, Kotsianidis I, Constantinidis TC.

Expert Rev Hematol. 2019 Dec;12(12):1063-1075. doi: 10.1080/17474086.2019.1668763. Epub 2019 Sep 24.

PMID:
31524011
9.

Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group.

Papageorgiou SG, Kontos CK, Kotsianidis I, Karousi P, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V.

J Geriatr Oncol. 2020 Jan;11(1):121-124. doi: 10.1016/j.jgo.2019.07.018. Epub 2019 Jul 27. No abstract available.

PMID:
31362867
10.

Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS).

Kotsianidis I, Papageorgiou SG, Pappa V, Galanopoulos AG, Viniou NA, Vassilakopoulos TP, Papoutselis M, Vrachiolias G, Papadopoulos V, Diamantopoulos PT, Tsokanas D, Kourakli A, Symeonidis A.

Mediterr J Hematol Infect Dis. 2019 Jul 1;11(1):e2019045. doi: 10.4084/MJHID.2019.045. eCollection 2019. No abstract available.

11.

Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.

Lamprianidou E, Zoulia E, Bernard E, Kordella C, Papoutselis M, Bezirgiannidou Z, Vrachiolias G, Papaemmanuil E, Kotsianidis I.

Leuk Lymphoma. 2019 Dec;60(13):3277-3281. doi: 10.1080/10428194.2019.1627542. Epub 2019 Jun 12. No abstract available.

PMID:
31185765
12.

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.

de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, Symeonidis A, Cermâk J, Hellström-Lindberg E, Stauder R, Sanz G, Mittelman M, Holm MS, Malcovati L, Mądry K, Germing U, Tatic A, Savic A, Almeida AM, Gredelj-Simec N, Guerci-Bresler A, Beyne-Rauzy O, Culligan D, Kotsianidis I, Itzykson R, van Marrewijk C, Blijlevens N, Bowen D, de Witte T; EUMDS Registry Participants.

Haematologica. 2020 Mar;105(3):632-639. doi: 10.3324/haematol.2018.212217. Epub 2019 Jun 6.

13.

Immunoporosis: A New Role for Invariant Natural Killer T (NKT) Cells Through Overexpression of Nuclear Factor-κB Ligand (RANKL).

Tilkeridis K, Kiziridis G, Ververidis A, Papoutselis M, Kotsianidis I, Kitsikidou G, Tousiaki NE, Drosos G, Kapetanou A, Rechova KV, Kazakos K, Spanoudakis E.

Med Sci Monit. 2019 Mar 23;25:2151-2158. doi: 10.12659/MSM.912119.

14.

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.

Diamantopoulos P, Koumbi D, Kotsianidis I, Pappa V, Symeonidis A, Galanopoulos A, Zikos P, Papadaki HA, Panayiotidis P, Dimou M, Hatzimichael E, Vassilopoulos G, Delimpasis S, Mparmparousi D, Papageorgiou S, Variami E, Kyrtsonis MC, Megalakaki A, Kotsopoulou M, Repousis P, Adamopoulos I, Kontopidou F, Christoulas D, Kourakli A, Tsokanas D, Konstantinos Papoutselis M, Kyriakakis G, Viniou NA; Hellenic MDS study group.

Cancer Med. 2019 May;8(5):2056-2063. doi: 10.1002/cam4.2090. Epub 2019 Mar 21.

15.

Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.

Diamantopoulos PT, Kontandreopoulou CN, Symeonidis A, Kotsianidis I, Pappa V, Galanopoulos A, Vassilakopoulos T, Dimou M, Solomou E, Kyrtsonis MC, Siakantaris M, Angelopoulou M, Kourakli A, Papageorgiou S, Christopoulou G, Roumelioti M, Panayiotidis P, Viniou NA; Hellenic MDS Study Group.

Ann Hematol. 2019 Jun;98(6):1383-1392. doi: 10.1007/s00277-019-03650-w. Epub 2019 Mar 15.

PMID:
30877373
16.

Isothiocyanate-induced Cell Cycle Arrest in a Novel In Vitro Exposure Protocol of Human Malignant Melanoma (A375) Cells.

Mantso T, Anestopoulos I, Lamprianidou E, Kotsianidis I, Pappa A, Panayiotidis MI.

Anticancer Res. 2019 Feb;39(2):591-596. doi: 10.21873/anticanres.13152.

PMID:
30711934
17.

Detection of CALR Mutations Using High Resolution Melting Curve Analysis (HRM-A); Application on a Large Cohort of Greek ET and MF Patients.

Giannopoulos A, Rougkala N, Loupis T, Mantzourani M, Viniou NA, Variami E, Vassilakopoulos TP, Dryllis G, Kotsianidis I, Gougopoulou T, Politou M, Konstantopoulos K, Vassilopoulos G.

Mediterr J Hematol Infect Dis. 2019 Jan 1;11(1):e2019009. doi: 10.4084/MJHID.2019.009. eCollection 2019.

18.

Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath?

Papalexandri A, Karypidou M, Stalika E, Kotta K, Touloumenidou T, Zerva P, Paleta A, Mallouri D, Batsis I, Sakellari I, Kotsianidis I, Anagnostopoulos A, Hadzidimitriou A, Margaritis D, Stamatopoulos K.

Leuk Lymphoma. 2019 Jul;60(7):1685-1692. doi: 10.1080/10428194.2018.1543881. Epub 2019 Jan 17.

PMID:
30652530
19.

Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.

Diamantopoulos PT, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Gogos D, Karakatsanis S, Papadaki H, Palla A, Hatzimichael E, Dimou M, Papageorgiou S, Delimpasis S, Papaioannou M, Papoutselis M, Kourakli A, Tsokanas D, Anagnostopoulos A, Kontos CK, Panayiotidis P, Viniou NA; Hellenic MDS study group.

Leuk Lymphoma. 2019 Jul;60(7):1721-1730. doi: 10.1080/10428194.2018.1540783. Epub 2018 Nov 14.

PMID:
30424699
20.

The JAK2V617F Point Mutation Increases the Osteoclast Forming Ability of Monocytes in Patients with Chronic Myeloproliferative Neoplasms and Makes their Osteoclasts more Susceptible to JAK2 Inhibition.

Spanoudakis E, Papoutselis M, Bazdiara I, Lamprianidi E, Kordella X, Tilkeridis C, Tsatalas C, Kotsianidis I.

Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018058. doi: 10.4084/MJHID.2018.058. eCollection 2018.

Supplemental Content

Loading ...
Support Center